Stocklytics Platform
Asset logo for symbol RLMD
Relmada Therapeutics
RLMD46
$3.40arrow_drop_up3.97%$0.13
Penny Stock
Asset logo for symbol RLMD
RLMD46

$3.40

arrow_drop_up3.97%

AI Deep-Learning Forecast (RLMD)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Relmada Therapeutics (RLMD) Stocklytics Forecast

According to market analysts, Relmada Therapeutics Inc (RLMD) is expected to experience significant growth in the coming years. With a focus on developing innovative therapies for treating central nervous system (CNS) disorders, RLMD has positioned itself as a key player in the biopharmaceutical industry.
Experts predict that RLMD stock price will continue to rise in the near future due to several factors. First and foremost, the company's robust pipeline of potential treatments for various CNS disorders is seen as a major catalyst for growth. These include therapies for depression, schizophrenia, and neuropathic pain, among others.
add Relmada Therapeutics  to watchlist

Keep an eye on Relmada Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Relmada Therapeutics (RLMD) stock?

Analysts have set a target price of $41.57 for Relmada Therapeutics (RLMD), based on forecasts from 7 analysts. The predicted price range extends from a high of $81 to a low of $8. This represents a potential increase of up to 2.28K% and a decrease of 135.29% from the current price of $3.4. These forecasts are as of 2019 Dec 16.
help

What are the analyst ratings for Relmada Therapeutics (RLMD) stock?

Currently, there are no analyst ratings available for Relmada Therapeutics (RLMD), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Relmada Therapeutics (RLMD) stock?

At present, there is no AI or machine-learning-based price prediction available for Relmada Therapeutics (RLMD) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media